Synopsis:
Ankylosing spondylitis is a progressive disease that should be monitored routinely throughout a patient’s life. IL-23 should be used as a clinical marker, and the findings can be strengthened by the combined information obtained from Ankylosing Spondylitis activity indexes analyses.